AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29694464 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and orofacial group (COG)
Number of subjects: 45
Study 29694464 — intervention group
Group type: COMPARATOR
Intervention: Cervical group (CG)
Number of subjects: 45
Study 27760129 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec/insulin aspart (IDegAsp) once daily (OD)
Number of subjects: 530
Study 27760129 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine U100 (IGlar) once daily (OD)
Number of subjects: 530
Study 24188161 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (100 mg/day)
Number of subjects: 321
Study 24188161 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran (200 mg/day)
Number of subjects: 321
Study 24188161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 321
Study 22500253 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (RTX) instillation plus hydrodistention
Number of subjects: 18
Study 22500253 — intervention group
Group type: COMPARATOR
Intervention: Hydrodistention only
Number of subjects: 18
Study 19834467 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity (PA) intervention involving moderate intensity aerobic, strength, balance, and flexibility exercise (150 min per week)
Number of subjects: 424
Study 19834467 — intervention group
Group type: COMPARATOR
Intervention: Successful aging (SA) intervention involving weekly educational workshops
Number of subjects: 424
Study 18453642 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal intervention (Taiji exercises, cognitive-behavioral therapies, support group)
Number of subjects: 43
Study 18453642 — intervention group
Group type: COMPARATOR
Intervention: Attention-control educational programs
Number of subjects: 43
Study 15824252 — intervention group
Group type: EXPERIMENTAL
Intervention: STN stimulation
Number of subjects: 23
Study 15824252 — intervention group
Group type: EXPERIMENTAL
Intervention: GPi stimulation
Number of subjects: 23
Study 12877571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 250 mg (formulation A)
Number of subjects: 24
Study 12877571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg (formulation B)
Number of subjects: 24
Study 12877571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg (formulation A)
Number of subjects: 24
Study 12877571 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation 500 mg (formulation C)
Number of subjects: 24
Study 12877571 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation 750 mg (formulation B)
Number of subjects: 24
Study 10823406 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (dFEN)
Number of subjects: 13
Study 10823406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 8889283 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg moclobemide b.i.d. for 16 days
Number of subjects: 24
Study 8889283 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg selegiline b.i.d. for 16 days
Number of subjects: 24
Study 8889283 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of moclobemide and selegiline
Number of subjects: 24
Study 8889283 — intervention group
Group type: COMPARATOR
Intervention: Moclobemide monotreatment
Number of subjects: 24
Study 1905394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG‐fermented milk product, 125 g (10(10‐11) colony‐forming units) twice daily (group 1)
Number of subjects: 71
Study 1905394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG freeze‐dried powder, one dose (10(10‐11) colony‐forming units) twice daily (group 2)
Number of subjects: 71
Study 1905394 — intervention group
Group type: COMPARATOR
Intervention: Placebo, a pasteurized yogurt, 125 g twice daily (group 3)
Number of subjects: 71
Study 6359379 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumovax (14-valent pneumococcal vaccine)
Number of subjects: 405
Study 6359379 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 405
Study 30277569 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT+)
Number of subjects: 125
Study 30277569 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (RT-)
Number of subjects: 125
Study 27548644 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch-up (ABC)
Number of subjects: 24
Study 27548644 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 24
Study 24567288 — intervention group
Group type: EXPERIMENTAL
Intervention: Community approaches (e.g., Chinese schools, stores, health fairs, and personal networks)
Number of subjects: 1119
Study 24567288 — intervention group
Group type: COMPARATOR
Intervention: Physician letter followed by telephone calls
Number of subjects: 1119
Study 22831821 — intervention group
Group type: EXPERIMENTAL
Intervention: Request for consent by a member of the research study team
Number of subjects: 1109
Study 22831821 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of the child (≥4 years)
Number of subjects: 1109
Study 22831821 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of vesicoureteric reflux
Number of subjects: 1109
Study 22831821 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient management of the index infection
Number of subjects: 1109
Study 22831821 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple (≥4) symptoms at presentation
Number of subjects: 1109
Study 20399327 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 17706
Study 20399327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17706
Study 17952791 — intervention group
Group type: EXPERIMENTAL
Intervention: Dug wells
Number of subjects: 640
Study 17952791 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-pitcher filters
Number of subjects: 640
Study 17952791 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 640
Study 16313377 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued support from a stroke nurse
Number of subjects: 176
Study 16313377 — intervention group
Group type: COMPARATOR
Intervention: Usual care and follow‐up
Number of subjects: 176
Study 12423299 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-Incision (SI)
Number of subjects: 36
Study 12423299 — intervention group
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft (FGG)
Number of subjects: 36
Study 12423299 — intervention group
Group type: COMPARATOR
Intervention: Trap-Door (TD)
Number of subjects: 36
Study 9695714 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C19 in patients with liver disease
Number of subjects: 28
Study 9695714 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6 in patients with liver disease
Number of subjects: 28
Study 9695714 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 28
Study 8083452 — intervention group
Group type: EXPERIMENTAL
Intervention: nedocromil sodium (4 mg) four times a day for 10 weeks
Number of subjects: 110
Study 8083452 — intervention group
Group type: COMPARATOR
Intervention: placebo four times a day for 10 weeks
Number of subjects: 110
Study 2729661 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 80
Study 2729661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6% parachlorometaxylenol
Number of subjects: 80
Study 2729661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% triclosan
Number of subjects: 80
Study 2729661 — intervention group
Group type: COMPARATOR
Intervention: Nonantimicrobial control soap
Number of subjects: 80
Study 2729661 — intervention group
Group type: EXPERIMENTAL
Intervention: All products (6 times/day)
Number of subjects: 80
Study 47421 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyglycolic-acid subcuticular skin closure
Number of subjects: 152
Study 47421 — intervention group
Group type: COMPARATOR
Intervention: Interrupted silk skin closure
Number of subjects: 152
Study 30408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-culturing normal MSCs with myeloma cells
Number of subjects: 0
Study 30408155 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant IGFBP2
Number of subjects: 0
Study 30408155 — intervention group
Group type: COMPARATOR
Intervention: MSCs from patients with MM
Number of subjects: 0
Study 30408155 — intervention group
Group type: COMPARATOR
Intervention: IGFBP2+ small adipocytes
Number of subjects: 0
Study 28196674 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-dense chemotherapy
Number of subjects: 0
Study 28196674 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 0
Study 26293573 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking position
Number of subjects: 60
Study 26293573 — intervention group
Group type: COMPARATOR
Intervention: Classical holding position
Number of subjects: 60
Study 23749622 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized patient education program
Number of subjects: 434
Study 23749622 — intervention group
Group type: COMPARATOR
Intervention: Traditional education program
Number of subjects: 434
Study 21377691 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (50mg)
Number of subjects: 39
Study 21377691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 19643809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat, high-fiber, high-fruit and -vegetable diet (strict adherence)
Number of subjects: 1905
Study 19643809 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 1905
Study 17466698 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P) 341 mg intramuscularly, twice each week until gestational week 36
Number of subjects: 60
Study 17466698 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 60
Study 17466698 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha-hydroxyprogesterone caproate (17P)
Number of subjects: 60
Study 14731152 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care-based patient education programme
Number of subjects: 194
Study 11583724 — intervention group
Group type: EXPERIMENTAL
Intervention: 17 beta E(2)‐D
Number of subjects: 121
Study 11583724 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE‐N
Number of subjects: 121
Study 11583724 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (17 beta E(2)‐D and CEE‐N)
Number of subjects: 121
Study 11583724 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 8980206 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program
Number of subjects: 439
Study 8980206 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 439
Study 8980206 — intervention group
Group type: COMPARATOR
Intervention: Health education program
Number of subjects: 439
Study 8102669 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (50,000 IU)
Number of subjects: 191
Study 8102669 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 191
Study 3521487 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% arildone cream
Number of subjects: 145
Study 3521487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 145
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg leuprorelin acetate (LA) (n = 40)
Number of subjects: 200
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.88 mg leuprorelin acetate (LA) (n = 40)
Number of subjects: 200
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena implantation (n = 40)
Number of subjects: 200
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena implantation after treatment with 3.75 mg LA (n = 40)
Number of subjects: 200
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirena implantation after treatment with 1.88 mg LA (n = 20)
Number of subjects: 200
Study 29552942 — intervention group
Group type: EXPERIMENTAL
Intervention: San-Jie-Zhen-Tong capsules alone (n = 20)
Number of subjects: 200
Study 26986919 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents and Tots Together (PTT) intervention, n = 27
Number of subjects: 48
Study 26986919 — intervention group
Group type: COMPARATOR
Intervention: Attention-matched control home safety intervention, n = 21
Number of subjects: 48
Study 25238251 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2374697 (AlbudAb)
Number of subjects: 0
Study 22214264 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia-care mapping intervention
Number of subjects: 0
Study 22214264 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 0
Study 19641984 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 23
Study 19641984 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 23
Study 17134892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years
Number of subjects: 1724
Study 17134892 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 1724
Study 17134892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years (in node-positive subgroup)
Number of subjects: 1724
Study 17134892 — intervention group
Group type: COMPARATOR
Intervention: Control (in node-positive subgroup)
Number of subjects: 1724
Study 17134892 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg daily for 3 years (in ER and PR positive subgroup)
Number of subjects: 1724
Study 17134892 — intervention group
Group type: COMPARATOR
Intervention: Control (in ER and PR positive subgroup)
Number of subjects: 1724
Study 15915033 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia (4 days of continuous infusion of 4 ml/h bupivacaine, 0.125%, and 50 mug/ml morphine)
Number of subjects: 60
Study 15915033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15915033 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative epidural analgesia
Number of subjects: 60
Study 12495789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine psychotherapy (KPT) with a high dose of ketamine (2.0 mg/kg im)
Number of subjects: 70
Study 12495789 — intervention group
Group type: COMPARATOR
Intervention: Ketamine psychotherapy (KPT) with a low dose of ketamine (0.2 mg/kg im)
Number of subjects: 70
Study 7644901 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched commands (e.g., 'wave your hands as a conductor')
Number of subjects: 0
Study 7644901 — intervention group
Group type: COMPARATOR
Intervention: Basic commands (e.g., 'wave your hands')
Number of subjects: 0
Study 7644901 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaboration
Number of subjects: 0
Study 2671059 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg of brotizolam
Number of subjects: 36
Study 2671059 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg of flurazepam
Number of subjects: 36
Study 2671059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 939814 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional teaching of biostatistics
Number of subjects: 0
Study 939814 — intervention group
Group type: COMPARATOR
Intervention: Lecture method
Number of subjects: 0
Study 31613133 — intervention group
Group type: EXPERIMENTAL
Intervention: Prioritizing positivity plus microintervention
Number of subjects: 240
Study 31613133 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation
Number of subjects: 240
Study 31613133 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Number of subjects: 240
Study 31613133 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial exposure to either meditation type
Number of subjects: 240
Study 31613133 — intervention group
Group type: COMPARATOR
Intervention: Control passage
Number of subjects: 240
Study 30771737 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine (35 mg bid)
Number of subjects: 6007
Study 30771737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6007
Study 28292385 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin-C injection 1 month before surgery
Number of subjects: 60
Study 28292385 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-C injection 24 hours before surgery
Number of subjects: 60
Study 26086783 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Gluconate‐containing securement dressing
Number of subjects: 1000
Study 26086783 — intervention group
Group type: COMPARATOR
Intervention: Non‐antimicrobial transparent dressings
Number of subjects: 1000
Study 23782625 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthodontic tooth movement initiated 2 to 4 weeks after tooth extraction
Number of subjects: 40
Study 23782625 — intervention group
Group type: COMPARATOR
Intervention: Orthodontic tooth movement initiated >12 weeks after tooth extraction
Number of subjects: 40
Study 20704642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% hydroalcoholic testosterone gel (50 mg/5 g gel), increased to 10 mg if clinically unsatisfactory
Number of subjects: 173
Study 20704642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 19558654 — intervention group
Group type: COMPARATOR
Intervention: Sulphadoxine-pyrimethamine (SP) 25/1.25 mg per kg on day 0
Number of subjects: 411
Study 19558654 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate plus sulphadoxine-pyrimethamine (AS/SP) 25/1.25 mg per kg on day 0 plus 4 mg/kg artesunate on days 0, 1, and 2
Number of subjects: 411
Study 17116835 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone plus azathioprine
Number of subjects: 40
Study 17116835 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone plus mycophenolate mofetil
Number of subjects: 40
Study 15490268 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily for 360 days
Number of subjects: 16
Study 11309547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg once daily, 400 mg on day 1)
Number of subjects: 12
Study 11309547 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg once daily)
Number of subjects: 12
Study 11309547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9603272 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's sensitive approach to drug-user treatment
Number of subjects: 0
Study 9603272 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment discharge status
Number of subjects: 0
Study 7844298 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride-releasing resin in composite restoration
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Cracked grains
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse flour
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine flour
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine maize meal
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole groats, rolled oats, fine oatmeal
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat flour
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat-based meals
Number of subjects: 0
Study 2451416 — intervention group
Group type: EXPERIMENTAL
Intervention: All three cereals (wheat, maize, oats)
Number of subjects: 0
Study 30402963 — intervention group
Group type: EXPERIMENTAL
Intervention: MMB-PLIF
Number of subjects: 101
Study 30402963 — intervention group
Group type: COMPARATOR
Intervention: CO-PLIF
Number of subjects: 101
Study 28272402 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral glutamine supplementation (30g for 5 weeks)
Number of subjects: 73
Study 28272402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 26515712 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Seeking Safety (25 sessions of 90 minutes each)
Number of subjects: 40
Study 26515712 — intervention group
Group type: COMPARATOR
Intervention: Facilitated Twelve-Step (25 sessions of 90 minutes each)
Number of subjects: 40
Study 26515712 — intervention group
Group type: EXPERIMENTAL
Intervention: Engaged in therapy (attended ≥ 6 sessions)
Number of subjects: 40
Study 23053464 — intervention group
Group type: EXPERIMENTAL
Intervention: M4 (magnesium, 4 g)
Number of subjects: 24
Study 23053464 — intervention group
Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 24
Study 21741220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45mg
Number of subjects: 121
Study 21741220 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 19170455 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Intervention (BMI)
Number of subjects: 198
Study 19170455 — intervention group
Group type: COMPARATOR
Intervention: Alcohol 101 Plus computer program
Number of subjects: 198
Study 19170455 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 198
Study 19170455 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI and Alcohol 101 Plus computer program
Number of subjects: 198
Study 17057135 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 17057135 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelofusine
Number of subjects: 8
Study 14688656 — intervention group
Group type: EXPERIMENTAL
Intervention: Optiva 2
Number of subjects: 100
Study 14688656 — intervention group
Group type: COMPARATOR
Intervention: Venflon 2
Number of subjects: 100
Study 14688656 — intervention group
Group type: COMPARATOR
Intervention: Biovalve
Number of subjects: 100
Study 10686571 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous light handrail support
Number of subjects: 15
Study 10686571 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous very light handrail support
Number of subjects: 15
Study 10686571 — intervention group
Group type: COMPARATOR
Intervention: No handrail support
Number of subjects: 15
Study 9492915 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrantel pamoate at a single dose rate of 10 mg/kg body weight
Number of subjects: 29